ENTA - Enanta Pharmaceuticals, Inc.
| Previous Close | 70.75 |
| Open | 70.28 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 1000 |
| Day's Range | 69.59 - 72.42 |
| 52 Week Range | 64.08 - 106.80 |
| Volume | 165,137 |
| Avg. Volume | 193,450 |
| Market Cap | 1.376B |
| Beta (3Y Monthly) | 1.03 |
| PE Ratio (TTM) | 22.78 |
| EPS (TTM) | 3.07 |
| Earnings Date | Nov 21, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 107.57 |
- Business Wire
Enanta Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.
- Thomson Reuters StreetEvents
Edited Transcript of ENTA earnings conference call or presentation 6-Aug-19 8:30pm GMT
Q3 2019 Enanta Pharmaceuticals Inc Earnings Call
- Simply Wall St.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA): What Does Its Beta Value Mean For Your Portfolio?
Anyone researching Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) might want to consider the historical volatility of the...
Motley FoolEnanta Pharmaceuticals, Inc. (ENTA) Q2 2019 Earnings Call Transcript
ENTA earnings call for the period ending June 30, 2019.
- Zacks
Enanta Pharmaceuticals (ENTA) Q3 Earnings Surpass Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 371.43% and -4.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2019
Webcast and Conference Call today at 4:30 p.m. ET
- Business Wire
Enanta’s HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET™ (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve HCV Patients with Compensated Cirrhosis
WATERTOWN, Mass.-- -- MAVIRET™ is now available as a shorter, 8-week, once-daily option for treatment-naïve, compensated cirrhotic, chronic hepatitis C patients with genotype 1, 2, 4, 5 or 6 Marketing authorization is supported by 97.9 percent cure* rate across this group of patients with no reported virologic failures Analysis evaluating MAVIRET as an 8-week, once-daily treatment option for treatment-naïve, ...
- Zacks
Enanta Pharmaceuticals (ENTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Enanta Pharmaceuticals (ENTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Enanta Pharmaceuticals to Host Conference Call on August 6 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2019
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2019 after the U.S. markets close on August 6, 2019. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline. Enanta will host a conference call and webcast on August 6 at 4:30 p.m. ET.
- Zacks
Enanta Pharmaceuticals (ENTA) Upgraded to Strong Buy: Here's What You Should Know
Enanta Pharmaceuticals (ENTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- Business Wire
Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus (HBV)
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has initiated part 1 of a Phase 1a/b clinical study of EDP-514, Enanta’s lead core inhibitor for the treatment of hepatitis B virus (HBV). The randomized, double-blind, placebo-controlled Phase 1a/b study is designed to evaluate first the safety, tolerability and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of EDP-514 in healthy subjects (Part 1), and then the antiviral activity of EDP-514 in nucleos(t)ide-reverse-transcriptase (NUC)-suppressed patients with chronic HBV infection (Part 2). Following the completion of the SAD and MAD portion in healthy subjects, the study will evaluate safety, PK and antiviral data of EDP-514 in NUC-suppressed patients with chronic HBV infection.
- Benzinga
Enanta's Respiratory Virus Drug Aces Midstage Study
The thinly traded, small-cap biotech Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) announced results Friday from a midstage study. What Happened Enanta released top-line results from a Phase 2a study that ...
- Simply Wall St.
How Much Did Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Pocket Last Year?
Jay Luly became the CEO of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in 2003. This analysis aims first to contrast...
- Reuters
UPDATE 1-Enanta's lung infection therapy succeeds in mid-stage trial
Enanta Pharmaceuticals Inc said on Friday its treatment for a highly contagious respiratory infection met the main goal of reducing virus levels in the body in a mid-stage study. The therapy, EDP-938, developed for treating respiratory syncytial virus (RSV) infection which currently has no available treatment, also helped improve symptoms in patients compared to placebo, the company said. RSV could lead to serious lung infections and even death in babies and the elderly who have a weaker immune system.
- Business Wire
Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced topline results that demonstrated that EDP-938 achieved highly statistically significant (p
- Business Wire
Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.
- CNW Group
AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies
AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies
- Thomson Reuters StreetEvents
Edited Transcript of ENTA earnings conference call or presentation 7-May-19 8:30pm GMT
Q2 2019 Enanta Pharmaceuticals Inc Earnings Call
- Simply Wall St.
Do Enanta Pharmaceuticals's (NASDAQ:ENTA) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- Business Wire
Enanta Pharmaceuticals to Present at Upcoming Investor Conference
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.
- Zacks
Enanta Pharmaceuticals (ENTA) Beats Q2 Earnings Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 322.22% and -1.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot
On a per-share basis, the Watertown, Massachusetts-based company said it had net income of 20 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
- Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019
Webcast and Conference Call today at 4:30 p.m. ET
